Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Pentoxifylline for sickle-cell disease.

J T Sherer¹, P H Glover

¹Methodist Hospital, Houston, TX 77030, USA. jsherer@tmh.tmc.edu

The Annals of Pharmacotherapy

|September 12, 2000

Summary

Pentoxifylline shows potential for treating sickle-cell disease (SCD) vasoocclusive episodes (VOEs). However, current evidence is limited, necessitating further research before routine recommendation for VOE prevention or treatment in SCD patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Insulin and coronary artery disease: is syndrome X the unifying hypothesis?

The Annals of pharmacotherapy·1998

Same author

Management of obesity: medical treatment options.

American family physician·1997

Same author

AIDS education in schools--awareness, attitudes and opinions among educators, theology students and health professionals.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1993

See all related articles

Area of Science:

Hematology
Pharmacology
Clinical Medicine

Background:

Sickle-cell disease (SCD) is characterized by painful vasoocclusive episodes (VOEs).
Pentoxifylline is investigated for its hemorheologic properties, including increased red blood cell deformability and anti-platelet aggregation effects.

Observation:

Laboratory and animal studies, along with case reports, suggest potential benefits of pentoxifylline in SCD.
Clinical studies evaluating pentoxifylline for VOEs in SCD are limited and often suffer from methodological weaknesses and inadequate data analysis.

Findings:

Preliminary data indicate pentoxifylline may be beneficial in treating an ongoing VOE.
No robust evidence currently supports the use of chronic pentoxifylline therapy for reducing the frequency of VOEs in sickle-cell disease.

Implications:

The efficacy of pentoxifylline for both prevention and treatment of VOEs in SCD remains poorly documented.
Further high-quality clinical trials are required to establish the role of pentoxifylline in SCD management.

Related Experiment Videos